Several ongoing studies are looking at the use of GLP-1 medications in type 1 diabetes, Shah says, including one he led, which will be presented in at the American Diabetes Associations annual meeting in June
in: PubMed | Google Scholar | Published October 16, 2025 - More info Long-chain fatty acid oxidation disorders (LC-FAODs) cause energy deficits in heart and skeletal muscle that are only partially corrected by current medium-chain lipid therapies such as triheptanoin
So (they) really havent seen whats happened with this. WHYY is your source for fact-based, in-depth journalism and information
[NAPQI toxicity studies - see full reference list] 77-79
Ensure you understand why both medications are necessary, what outcomes are expected, and whether alternative treatment approaches might be suitable
Compounded tirzepatide is advertised at $199/month, or about $298/month all-in